التفاصيل البيبلوغرافية
| العنوان: |
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody‐mediated T‐cell cytotoxicity. |
| المؤلفون: |
Godwin, Colin D.1,2 (AUTHOR), Bates, Olivia M.1 (AUTHOR), Garling, Eliotte E.1 (AUTHOR), Beddoe, Mary E.1 (AUTHOR), Laszlo, George S.1 (AUTHOR), Walter, Roland B.1,2,3,4 (AUTHOR) rwalter@fredhutch.org |
| المصدر: |
British Journal of Haematology. Apr2020, Vol. 189 Issue 1, pe9-e13. 5p. 2 Graphs. |
| مصطلحات موضوعية: |
*PROTEIN-tyrosine kinases, *KINASE inhibitors, *T cell receptors, *CYTOLOGY |
| مستخلص: |
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity Keywords: acute leukaemia; bispecific antibody; Bruton's tyrosine kinase; ibrutinib; IL-2-inducible T-cell kinase EN acute leukaemia bispecific antibody Bruton's tyrosine kinase ibrutinib IL-2-inducible T-cell kinase e9 e13 5 03/31/20 20200401 NES 200401 Bispecific antibodies (BiAbs) have emerged as promising therapeutics for haematologic malignancies, with the CD19/CD3 Bispecific T-cell Engager blinatumomab approved for patient application and many more investigational agents in clinical testing (Viardot & Bargou, [15]). On the other hand, also recently reported in this journal, broad-spectrum tyrosine kinase inhibitors can acutely abrogate cytotoxicity of T-cell-directed BiAbs and CAR T-cells I in vitro i (Fasslrinner I et al. i , [6]). BiAb-mediated T-cell cytotoxicity depends on both T-cell and tumour cell factors (Viardot & Bargou, [15]). [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
